Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Public ClinicalTrials.gov record NCT02646319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
Study identification
- NCT ID
- NCT02646319
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 2 participants
Conditions and interventions
Conditions
- Advanced Malignant Neoplasm
- Cervical Squamous Cell Carcinoma
- Endometrial Carcinoma
- Malignant Uterine Neoplasm
- Recurrent Bladder Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Head and Neck Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Ovarian Carcinoma
- Recurrent Prostate Carcinoma
- Recurrent Renal Cell Carcinoma
- Solid Neoplasm
- Stage III Bladder Cancer
- Stage III Prostate Cancer
- Stage III Renal Cell Cancer
- Stage IIIA Breast Cancer
- Stage IIIA Cervical Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIB Breast Cancer
- Stage IIIB Cervical Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIC Breast Cancer
- Stage IIIC Ovarian Cancer
- Stage IV Breast Cancer
- Stage IV Ovarian Cancer
- Stage IV Prostate Cancer
- Stage IV Renal Cell Cancer
- Stage IVA Bladder Cancer
- Stage IVA Cervical Cancer
- Stage IVB Bladder Cancer
- Stage IVB Cervical Cancer
Interventions
- Laboratory Biomarker Analysis Other
- Nanoparticle Albumin-Bound Rapamycin Drug
- Quality-of-Life Assessment Other
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2015
- Primary completion
- Sep 4, 2017
- Completion
- Apr 23, 2018
- Last update posted
- Jun 5, 2019
2016 – 2018
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02646319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2019 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02646319 live on ClinicalTrials.gov.